



HAL
open science

The decline in stomach cancer mortality: exploration of future trends in seven European countries

Masoud Amiri, Fanny Janssen, Anton E. Kunst

► To cite this version:

Masoud Amiri, Fanny Janssen, Anton E. Kunst. The decline in stomach cancer mortality: exploration of future trends in seven European countries. *European Journal of Epidemiology*, 2010, 26 (1), pp.23-28. 10.1007/s10654-010-9522-9 . hal-00642417

HAL Id: hal-00642417

<https://hal.science/hal-00642417>

Submitted on 18 Nov 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The decline in stomach cancer mortality: exploration of future trends in seven European countries

Masoud Amiri^{a,b}, Fanny Janssen^c and Anton E Kunst^d

a- Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands

b-Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran

c- Population Research Centre, Faculty of Spatial Sciences, University of Groningen, Groningen, the Netherlands

d- Department of Public Health, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands

Corresponding Author: Masoud Amiri, Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands

Email: masoud.amiri@yahoo.com, Phone: +31-107043711 and +31-630964709, Fax: +31-107038475

Abstract

Mortality from stomach cancer has fallen steadily during the past decades. The aim of this paper is to assess the implication of a possible continuation of the decline in stomach cancer mortality until the year 2030. Annual rates of decline in stomach cancer mortality from 1980 to 2005 were determined for the Netherlands, United Kingdom, France, and four Nordic countries on the basis of regression analysis. Mortality rates were extrapolated until 2030, assuming the same rate of decline as in the past, using three possible scenarios. The absolute numbers of deaths were projected taking into account data on the ageing of national populations. Stomach cancer mortality rates declined between 1980 and 2005 at about the same rate (3.6-4.9 percent per year) for both men and women in all countries. The rate of decline did not level off in recent years, and it was not smaller in countries with lower overall mortality rates in 1980. If this decline were to continue into the future, stomach cancer mortality rates would decline with about 66 percent between 2005 and 2030 in most populations, while the absolute number of stomach cancer deaths would diminish by about 50 percent. Thus, in view of the strong, stable and consistent mortality declines in recent decades, and despite population ageing, stomach cancer is likely to become far less important as a cause of death in Europe in the future.

Key Words: Stomach cancer, mortality, trends, Europe, projections

Introduction

Stomach cancer is the fourth most frequent cancer^{1, 2} and the world's second leading cause of cancer mortality¹. However, it has been fallen throughout Europe during the past decades in terms of both incidence and mortality rates^{3, 4}, mainly as a result of remarkable improvement of living conditions in European societies⁵⁻⁸. Efforts to reduce global cancer disparities begin with an understanding of geographic patterns in cancer incidence, mortality and prevalence, by studies such as GLOBOCAN^{9, 10}, EUROCARE¹¹, and Five Continents databases¹². Survival increased and mortality decreased through the combination of earlier detection, better access to care and improved treatment¹³. There has also been a concomitant change in lifestyle and environmental exposures over successive generations¹⁴, including changes in exposures to risk factors in early life¹⁵.

Several studies conducted projections of future trends in stomach cancer mortality in European countries^{7, 12, 14-17}. Mortality rates were generally expected to decline further. Based on the cancer mortality trends in the European Union until 2000, one study projected a further fall by 11% in age-standardized cancer mortality from 2000 to 2015¹⁶. A Dutch study also projected a substantial decline in stomach cancer mortality until 2015, based on trends until 2000¹⁷. Similarly, an Irish study predicted mortality from stomach cancer to fall further in the near future, although at a slower rate than in the recent past¹⁸.

European studies included projections of the absolute number of cancer deaths, thereby taking into account the rapid ageing of European populations in the forthcoming decades¹⁴⁻¹⁶. Population ageing alone may induce a strong increase in the absolute number of incident cases and deaths for many types of cancer. However, in the case of stomach cancer, this demographic effect may be offset by an opposite epidemiological effect if the recent decline in age-specific mortality rates were to continue in the future.

The aim of this study was to assess, for seven European countries, the implications of a possible continuation of the recent declines in stomach cancer rates. Future trends were evaluated in terms of not only mortality rates, but also absolute numbers of death, thereby taking into account the ageing of national populations.

Projections of future mortality trends should be based on a careful analysis of trends in the past^{19, 20}. We therefore started the analysis with a description of trends in stomach cancer mortality over a long period, from 1980 up to 2005, in order to check whether mortality declines continued undiminished until recent years. In addition, we assessed whether the rate of decline was similar for all seven countries and both sexes, despite differences in overall levels of stomach mortality rates. We thus aimed to identify a stable and consistent long-term mortality trend that could serve as a basis for projections into the future. In addition, we formulated three scenarios to express uncertainties regarding future mortality trends.

Material and Methods

Data for Denmark, Finland, France metropolitan, the Netherlands, Norway, Sweden and England and Wales on the number of deaths from stomach cancer (ICD code 151 for ICD-8 and ICD-9, C16 for ICD-10²¹) and corresponding numbers of population at risk, by sex and five-year age groups for the years 1980 to 2005 have been obtained from Eurostat (Denmark from 1999-2001, France from 1998-2005, and other countries from 2000 to 2005) and national data sources (1980-1999)²². The

historical national data for England and Wales and France were transformed into data for United Kingdom and France metropolitan, by applying age and sex-specific correction factors, based on the comparison of stomach cancer mortality rates in 1995.

To describe trends in stomach cancer mortality between 1980 and 2005, sex-specific age-standardized mortality rates were calculated using direct standardization, taking the average national male and female populations by five year age groups over 2000-2005 (2000-2001 for Denmark) as the standard populations. In addition, we estimated sex- and country- specific annual mortality changes (%) over the period 1980-2005 by means of age-period log-linear regression analysis. The dependent variable was the number of deaths, with the person-years at risk (estimated by the midyear population) as offset variable. We used age by five year age groups (from 0 to 80+) (categorical) and single calendar year (continuous) as independent variables. Annual mortality changes (%) were calculated by this formula: $100 \cdot (\exp(b) - 1)$, in which b is the parameter estimate of the calendar year variable.

To project age, sex, and country-specific mortality rates until 2030, we assumed that the mortality trends in the past 25 years (from 1980 to 2005) would continue for the coming 25 years. Therefore, we applied the estimated annual changes in mortality in the period 1980-2005 for all age groups combined to average national age-specific mortality rates in 2000-2005.

To express uncertainties regarding future mortality trends, we formulated three scenarios. In the reference scenario, the future rate of change was assumed to be equal for all countries and therefore was calculated as the unweighted average of the rates of change of the seven countries. In the pessimistic scenario, we assumed the future rate of change to be equal to the slowest observed rate of change observed among all countries. In the optimistic scenario, we took the highest rate of change observed in the past. All three scenarios distinguished men and women.

The formula used to make projections, per country and sex, was: ${}_n M_x^{t_0+t} = {}_n M_x^{t_0} \cdot ({}_n c_x^* + 1)^t$, where M denotes the mortality rate in the age interval x to $x+n$. De year t is expressed as the difference with the baseline year t_0 (=2005); thus $t=25$ for the year 2030. The change factor c^* is the observed annual decline ($\exp(b)-1$) for all age groups combined, multiplied by a ratio expressing the annual decline in the age groups 40-59, 60-79, and 80+ relative to the annual decline for all age groups (unweighted average over all countries). In the reference scenario, the applied ratios for men were 0.92, 1.03, and 0.99 for the age groups 40-59, 60-79, and 80 and more, respectively; and the ratios for women were 0.85, 0.97, and 1.09, respectively.

Future stomach cancer mortality numbers were estimated by applying the future sex and age-specific rates to the projected age-specific population sizes for the different countries up to 2030. These future population numbers have been obtained from Eurostat (baseline variant), except for Norway for which the data have been obtained from Statistics Norway (medium national Growth variant) (<http://statbank.ssb.no/statistikbanken>). Looking into the projected mortality rates and absolute number of deaths in 2030, it can be measured if stomach cancer is a less important cause of death in the future.

Results

Figure 1 shows trends in age-standardized mortality rates between 1980 and 2005. In all countries, stomach cancer mortality rates declined steadily. The rate of decline is within a narrow range, from 3.61 percent per year for Norwegian men to 4.90 percent for Danish and Finnish women. The overall average rate of decline was

4.2 percent per year. The rate of decline remained similar over time for both sexes in most of these countries. There was no indication that the rate of decline (expressed in percent decline per year) had been levelling off in recent years. A main exception is the strong decline in mortality among Finnish women in the 1980's, when Finnish women were catching up with other countries.

In Figure 2, the rate of declines in stomach cancer mortality over the period 1980 to 2005 is plotted against the age-standardized mortality rates in 1980. The aim of this scatter plot is to assess whether the decline in stomach cancer mortality was higher in populations with higher initial mortality rates. However, both among men and women, no such positive association was found.

Table 1 presents projections for 2030 of stomach cancer mortality rates. Values projected for 2030 are compared to values observed for 2005 by means of ratios with 2005 as reference. In all seven European countries, age-standardized mortality rates would have declined in 2030 compared to 2005 if past trends were to continue. This decline would be substantial in all populations. The percentages of declines in 2030 compared to 2005 (calculated by one minus rate ratios or $1 - RR$) for men are -on average- 0.66, 0.59, and 0.75 for the reference, pessimistic, and optimistic scenarios, respectively. These figures for women are 0.67, 0.59, and 0.77 respectively.

Table 2 presents projections for 2030 of the absolute number of stomach cancer deaths. Values projected for 2030 are compared to values observed for 2005 by means of ratios with 2005 as reference. The decline in the absolute number of deaths would be substantial as well, although with more variability between countries. The percentages of declines (in 2030 compared to 2005) for men are -on average- 0.43, 0.32, and 0.59 for the reference, pessimistic, and optimistic scenarios, respectively. These figures for women are 0.54, 0.42, and 0.67 respectively.




Figure 1- Age-standardized stomach cancer mortality rates (per 100,000) in seven European countries by sex: 1980-2005 *

* Corresponding estimates of annual declines (%) for men (women) are for Denmark 4.60 (4.90), United Kingdom 3.96 (4.16), Finland 4.68 (4.90), France Metropolitan 3.67 (4.32), Netherlands 3.92 (3.81), Norway 3.61 (3.90), and Sweden 4.06 (4.11).




Figure 2- Annual declines (%) in stomach cancer mortality 1980-2005 against age-standardized mortality rates in 1980, by sex and country

Table 1– Stomach cancer mortality rates (age standardized, per 100,000), by scenario[#], country and sex, for 2005 (observed) and 2030 (projected)

	Year	Country						
		Denmark	United Kingdom	Finland	France	Netherlands	Norway	Sweden
Men								
	2005	7.40	12.95	11.09	9.87	11.40	10.37	10.27
Reference Scenario	2030	2.62	4.22	3.80	3.39	3.84	3.74	3.48
	2030/2005*	0.35	0.33	0.34	0.34	0.34	0.36	0.34
Pessimistic Scenario	2030	3.21	5.06	4.60	4.10	4.62	4.52	4.21
	2030/2005*	0.43	0.39	0.41	0.41	0.41	0.44	0.41
Optimistic Scenario	2030	1.87	3.08	2.78	2.47	2.80	2.71	2.52
	2030/2005*	0.25	0.24	0.25	0.25	0.25	0.26	0.24
Women								
	2005	4.73	8.02	8.69	5.49	6.70	8.44	6.22
Reference Scenario	2030	1.59	2.34	2.91	1.81	2.32	2.39	2.29
	2030/2005*	0.34	0.29	0.34	0.33	0.35	0.28	0.37
Pessimistic Scenario	2030	2.00	2.90	3.62	2.26	2.89	2.99	2.85
	2030/2005*	0.42	0.36	0.42	0.41	0.43	0.35	0.46
Optimistic Scenario	2030	1.14	1.68	2.13	1.28	1.69	1.71	1.65
	2030/2005*	0.24	0.21	0.24	0.23	0.25	0.20	0.27

* The figure for 2030 divided by the related figure for 2005.

For Denmark, the values for 2005 are not observed but projected.

Reference scenario = Equal future rate of change for all countries; Pessimistic scenario = Slowest observed rate of change for all countries; Optimistic scenario = Highest rate of change for all countries.

Table 2– Stomach cancer absolute number of deaths, by scenario[#], country and sex, for 2005 (observed) and 2030 (projected)

	Year	Country						
		Denmark	United Kingdom	Finland	France	Netherlands	Norway	Sweden
Men								
	2005	209	3914	301	3045	963	242	470
Reference Scenario	2030 2030/2005*	112 0.54	2050 0.52	186 0.62	1675 0.55	556 0.58	155 0.64	240 0.51
Pessimistic Scenario	2030 2030/2005*	137 0.66	2467 0.63	225 0.75	2090 0.67	667 0.69	186 0.77	291 0.62
Optimistic Scenario	2030 2030/2005*	79 0.38	1480 0.38	133 0.44	1204 0.40	404 0.42	111 0.46	172 0.37
Women								
	2005	131	2475	240	1789	566	196	284
Reference Scenario	2030 2030/2005*	58 0.44	1021 0.41	119 0.50	877 0.49	290 0.51	81 0.41	138 0.49
Pessimistic Scenario	2030 2030/2005*	73 0.56	1266 0.51	148 0.62	1100 0.62	360 0.64	101 0.51	171 0.60
Optimistic Scenario	2030 2030/2005*	41 0.32	725 0.29	84 0.35	606 0.34	209 0.37	58 0.30	98 0.35

* The figure for 2030 divided by the related figure for 2005.

For Denmark, the values for 2005 are not observed but projected.

Reference scenario = Equal future rate of change for all countries; Pessimistic scenario = Slowest observed rate of change for all countries; Optimistic scenario = Highest rate of change for all countries.

Discussion

The strong decline in stomach cancer mortality was found to continue at an undiminished rate until 2005 in each of the seven European countries. If this decline were to continue into the future, stomach cancer mortality rates would decline with about 66 percent between 2005 and 2030. The absolute number of stomach cancer deaths would diminish by about 50 percent despite the ageing of national populations. Even though weaker declines were predicted in the pessimistic scenario, this scenario as well implied that stomach cancer would become far less important as a cause of death in Europe in the next decades.

A key factor for the past declines in stomach cancer mortality is a decrease in the exposure to *Helicobacter pylori* (*H. pylori*) infection²³. *H. pylori* prevalence had been found to decline in parallel with the decrease of incidence of stomach cancer²⁴. However, *H. Pylori* infection may not be the only factor. It has been estimated to account for only half of the global total burden of stomach cancer because of synergistic or antagonistic roles of dietary and other exogenous factors²⁵. Complementary explanations for the observed declines in stomach cancer mortality may include better food preservation and refrigeration, improvement in environmental conditions and lifestyle changes^{27,26}. Similarly, declines in the near future may still be largely driven by recent improvements in the living conditions that current generations had experienced during their childhood and adulthood.

Improved medical treatment may also have contributed to the decline in mortality from stomach cancer^{26, 27} like it contributed to the observed differences in stomach cancer mortality between European countries²⁷. Therefore, further advances in the treatment for stomach cancer and *H. pylori* infections may be important to maintain a strong decline in stomach cancer mortality rates in the future. This role is supported by the observation that, while the incidence of stomach cancer had declined as well, mortality rates seemed to have declined at faster rates, indicating a decline in case fatality rates¹⁴. However, we should note that different trends in incidence and mortality of cancer are found for most solid tumours, and may be a consequence of increased detection of early tumours with often good prognosis²⁸.

Empirical support for the expectation that the decline in mortality from stomach cancer will continue in the future comes from the trends that were observed for the past 25 years. Firstly, there is a strong consistency in the recent trends in stomach cancer mortality among both sexes and among each of the seven European countries. Second, these declines had persisted up to recent years in each of these populations, including those with the lowest initial mortality rates. Furthermore, steady declines in stomach cancer mortality were observed in the middle-aged and the young population as well, suggesting that they are likely to continue in the near future^{4, 5, 16}. The latter observation is consistent with observations of cohort-wise patterns of decline in stomach cancer mortality in European countries^{29 14, 30}, which may reflect the effects of improvement in living conditions in childhood²⁹.

It should be emphasized that, even though future declines may seem likely, our study was primarily aimed at exploring possible future trends by extrapolating past trends. This extrapolation provides a baseline scenario against which new studies may formulate more specific scenarios of future trends. For example, policy-based scenarios may focus on the potential effects of specific preventive policies or advancement in the treatment of stomach cancer. As stomach cancer may become ever less important in terms of mortality, scenario studies will need to also include measures of incidence, prognosis and prevalence of stomach cancer.

References

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. *World J Gastroenterol*. Jan 21 2006;12(3):354-362.
2. Prinz C, Schwendy S, Volland P. H pylori and gastric cancer: shifting the global burden. *World J Gastroenterol*. Sep 14 2006;12(34):5458-5464.
3. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. *J Clin Epidemiol*. Jan 2003;56(1):1-9.
4. Levi F, Lucchini F, Gonzalez JR, Fernandez E, Negri E, La Vecchia C. Monitoring falls in gastric cancer mortality in Europe. *Ann Oncol*. Feb 2004;15(2):338-345.
5. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. *Ann Oncol*. Apr 2008;19(4):631-640.
6. Lepage C, Remontet L, Launoy G, et al. Trends in incidence of digestive cancers in France. *Eur J Cancer Prev*. Feb 2008;17(1):13-17.
7. Levi F, Lucchini F, Negri E, La Vecchia C. Continuing declines in cancer mortality in the European Union. *Ann Oncol*. Mar 2007;18(3):593-595.
8. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. *CA Cancer J Clin*. Jan-Feb 2007;57(1):43-66.
9. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. *Int J Cancer*. Oct 15 2001;94(2):153-156.
10. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin*. Mar-Apr 2005;55(2):74-108.
11. Francisci S, Capocaccia R, Grande E, et al. The cure of cancer: a European perspective. *Eur J Cancer*. Apr 2009;45(6):1067-1079.
12. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol*. May 10 2006;24(14):2137-2150.
13. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. *Eur J Cancer*. Jul 2008;44(10):1345-1389.
14. Fitzsimmons D, Osmond C, George S, Johnson CD. Trends in stomach and pancreatic cancer incidence and mortality in England and Wales, 1951-2000. *Br J Surg*. Sep 2007;94(9):1162-1171.
15. Aragonés N, Pollán M, Ródero I, López-Abente G. Gastric cancer in the European Union (1968-1992): mortality trends and cohort effect. *Ann Epidemiol*. May 1997;7(4):294-303.
16. Quinn MJ, d'Onofrio A, Moller B, et al. Cancer mortality trends in the EU and acceding countries up to 2015. *Ann Oncol*. Jul 2003;14(7):1148-1152.
17. Coebergh JW. *Kanker in Nederland: KWF kankerbestrijding; 2004: 88-94*. Available from http://spitswww.uvt.nl/~Fmols/kanker_in_nederland.pdf.
18. O'Lorcain P, Deady S, Comber H. Mortality predictions for esophageal, stomach, and pancreatic cancer, Ireland, up to 2015. *Int J Gastrointest Cancer*. 2006;37(1):15-25.
19. Janssen F, Kunst A. The choice among past trends as a basis for the prediction of future trends in old-age mortality. *Popul Stud (Camb)*. Nov 2007;61(3):315-326.
20. Wilmoth JR. Demography of longevity: past, present, and future trends. *Exp Gerontol*. Dec 2000;35(9-10):1111-1129.
21. Janssen F, Kunst AE. ICD coding changes and discontinuities in trends in cause-specific mortality in six European countries, 1950-99. *Bull World Health Organ*. Dec 2004;82(12):904-913.

22. Janssen F, Mackenbach JP, Kunst AE. Trends in old-age mortality in seven European countries, 1950-1999. *J Clin Epidemiol*. Feb 2004;57(2):203-216.
23. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. *Ann Oncol*. Mar 2007;18(3):581-592.
24. Axon A. Helicobacter pylori: what do we still need to know? *J Clin Gastroenterol*. Jan 2006;40(1):15-19.
25. Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. *Public Health Nutr*. Feb 2004;7(1A):187-200.
26. Corley DA, Kubo A. Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. *J Natl Cancer Inst*. Sep 15 2004;96(18):1383-1387.
27. Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D. Explaining gastric cancer survival differences among European countries. *Int J Cancer*. May 1 2004;109(5):737-741.
28. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer*. Mar 2010;46(4):765-781.
29. Amiri M, Kunst AE, Janssen F, Mackenbach JP. Trends in stomach cancer mortality in relation to living conditions in childhood. A study among cohorts born between 1860 and 1939 in seven European countries. *Eur J Cancer*. Dec 2006;42(18):3212-3218.
30. La Vecchia C, Negri E, Levi F, Decarli A, Boyle P. Cancer mortality in Europe: effects of age, cohort of birth and period of death. *Eur J Cancer*. Jan 1998;34(1):118-141.